Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biohaven Pharmaceuticals, Inc.
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Eligible subjects are those subjects who complete study BHV4157-302 or BHV4157-303 and for whom the investigator believes open-label treatment offers an acceptable risk-benefit profile.
Determined by the investigator to be medically stable at the week 10 visit of BHV4157-302 or BHV4157-303, as assessed by medical history, physical examination, laboratory test results, and electrocardiogram testing.
It is required that all women of child-bearing potential (WOCBP) who are sexually active agree to use two methods of contraception for the duration of the study
You may not be if
Subjects who did not successfully complete 10 weeks of treatment in the BHV4157-302 or BHV4157-303 study.
Acute suicidality or suicide attempt or self injurious behavior in the last 12 months.
Patients who may have received a non-biological investigational agent in any clinical trial within 30 days or a biological agent within 90 days prior to entry, other than what was received in BHV4157-302 or BHV4157-303;
Clareo Health | Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorder
